Literature DB >> 8137128

Scrapie pathogenesis.

J R Scott1.   

Abstract

There is no specific marker for scrapie infectivity, and therefore no means other than prolonged bioassay for estimating levels of infection in tissues. Our knowledge of replication dynamics depends on precise rodent models which have enabled us to determine how the disease spreads and in which cells it replicates. We know, firstly, that infection replicates in the lymphoreticular system, and can identify a candidate cell; secondly, the factors which control the length of the disease process, and how difficult it is to influence this; thirdly, that clinical disease depends on access to the nervous system, and that once neuroinvasion has occurred, the spread of infectivity in both PNS and CNS is along neuroanatomical pathways at a similar rate to slow axonal transport in uninfected mice. Infecting the visual pathways of the CNS through the retina has shown that spongiform pathology occurs as a consequence of replication, and that the Sinc gene, which has a major effect on incubation period length in mice, acts by controlling the initiation, but not the rate, of replication. The localisation of PrP, a host protein of unknown function which accumulates in an abnormal form in diseased animals provides an important pointer to pathogenetic mechanisms.

Entities:  

Mesh:

Year:  1993        PMID: 8137128     DOI: 10.1093/oxfordjournals.bmb.a072646

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  9 in total

1.  The role of the cytoskeleton in the life cycle of viruses and intracellular bacteria: tracks, motors, and polymerization machines.

Authors:  E L Bearer; P Satpute-Krishnan
Journal:  Curr Drug Targets Infect Disord       Date:  2002-09

Review 2.  The spatial dynamics of prion disease.

Authors:  R J Payne; D C Krakauer
Journal:  Proc Biol Sci       Date:  1998-12-07       Impact factor: 5.349

3.  Death Receptor 6 and Caspase-6 Regulate Prion Peptide-Induced Axonal Degeneration in Rat Spinal Neurons.

Authors:  Yunsheng Wang; Deming Zhao; Bo Pan; Zhiqi Song; Syed Zahid Ali Shah; Xiaomin Yin; Xiangmei Zhou; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2015-04-22       Impact factor: 3.444

4.  Modification of blood cell PrP epitope exposure during prion disease.

Authors:  Alana M Thackray; Stephen J Ryder; Raymond Bujdoso
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

5.  Toll-like receptor 2 deficiency shifts PrP106-126-induced microglial activation from a neurotoxic to a neuroprotective phenotype.

Authors:  Jihong Wang; Deming Zhao; Bo Pan; Yongyao Fu; Fushan Shi; Mohammed Kouadir; Lifeng Yang; Xiaomin Yin; Xiangmei Zhou
Journal:  J Mol Neurosci       Date:  2014-10-21       Impact factor: 3.444

6.  Microglial cell line established from prion protein-overexpressing mice is susceptible to various murine prion strains.

Authors:  Yoshifumi Iwamaru; Takato Takenouchi; Kazumasa Ogihara; Megumi Hoshino; Masuhiro Takata; Morikazu Imamura; Yuichi Tagawa; Hiroko Hayashi-Kato; Yuko Ushiki-Kaku; Yoshihisa Shimizu; Hiroyuki Okada; Morikazu Shinagawa; Hiroshi Kitani; Takashi Yokoyama
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

7.  C-Abl tyrosine kinase mediates neurotoxic prion peptide-induced neuronal apoptosis via regulating mitochondrial homeostasis.

Authors:  Bo Pan; Lifeng Yang; Jin Wang; Yunsheng Wang; Jihong Wang; Xiangmei Zhou; Xiaomin Yin; Zhongqiu Zhang; Deming Zhao
Journal:  Mol Neurobiol       Date:  2014-02-08       Impact factor: 5.590

Review 8.  Research progress on the NLRP3 inflammasome and its role in the central nervous system.

Authors:  Shen-Bin Liu; Wen-Li Mi; Yan-Qing Wang
Journal:  Neurosci Bull       Date:  2013-03-20       Impact factor: 5.203

9.  The NALP3 inflammasome is involved in neurotoxic prion peptide-induced microglial activation.

Authors:  Fushan Shi; Lifeng Yang; Mohammed Kouadir; Yang Yang; Jihong Wang; Xiangmei Zhou; Xiaomin Yin; Deming Zhao
Journal:  J Neuroinflammation       Date:  2012-07-11       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.